Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DUSA, Schering deal

SCH returned development and marketing rights for Levulan photodynamic therapy

Read the full 106 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE